Jens Bukh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6135527/publications.pdf

Version: 2024-02-01

203 papers	18,448 citations	14655 66 h-index	12946 131 g-index
225 all docs	225 docs citations	225 times ranked	10985 citing authors

#	Article	IF	Citations
1	Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005, 42, 962-973.	7.3	1,303
2	Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology, 2014, 59, 318-327.	7.3	1,141
3	Genomic analysis of the host response to hepatitis C virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15669-15674.	7.1	796
4	Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and Genotypes. Seminars in Liver Disease, 1995, 15, 41-63.	3.6	774
5	Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15661-15668.	7.1	581
6	ICTV Virus Taxonomy Profile: Flaviviridae. Journal of General Virology, 2017, 98, 2-3.	2.9	537
7	Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of aâ€‰chimpanzee. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8738-8743.	7.1	495
8	Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Archives of Virology, 1998, 143, 2493-2503.	2.1	427
9	Sequence analysis of the 5' noncoding region of hepatitis C virus.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 4942-4946.	7.1	421
10	A virus discovery method incorporating DNase treatment and its application to the identification of two bovine parvovirus species. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11609-11614.	7.1	356
11	Genetic Epidemiology of Hepatitis C Virus throughout Egypt. Journal of Infectious Diseases, 2000, 182, 698-707.	4.0	336
12	Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology, 2009, 49, 364-377.	7.3	333
13	Sequence analysis of the core gene of 14 hepatitis C virus genotypes.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8239-8243.	7.1	306
14	Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6205-6210.	7.1	306
15	In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14199-14204.	7.1	297
16	Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae. Journal of General Virology, 2017, 98, 2106-2112.	2.9	264
17	The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. Journal of General Virology, 2011, 92, 233-246.	2.9	251
18	Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 14416-14421.	7.1	244

#	Article	IF	Citations
19	Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4560-4565.	7.1	231
20	Transcripts of a Chimeric cDNA Clone of Hepatitis C Virus Genotype 1b Are Infectiousin Vivo. Virology, 1998, 244, 161-172.	2.4	205
21	The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11646-11651.	7.1	204
22	Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate. PLoS Pathogens, 2012, 8, e1002653.	4.7	201
23	The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. Journal of Hepatology, 2016, 65, S2-S21.	3.7	195
24	MicroRNA-122 antagonism against hepatitis C virus genotypes 1â€“6 and reduced efficacy by host RNA insertion or mutations in the HCV 5â€² UTR. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 4991-4996.	7.1	182
25	Hepatitis C Virus: An Infectious Molecular Clone of a Second Major Genotype (2a) and Lack of Viability of Intertypic 1a and 2a Chimeras. Virology, 1999, 262, 250-263.	2.4	169
26	Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a/2a (S52/JFH1) Viruses. Gastroenterology, 2007, 133, 1614-1626.	1.3	168
27	Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 997-1002.	7.1	167
28	A critical role for the chimpanzee model in the study of hepatitis C. Hepatology, 2004, 39, 1469-1475.	7.3	166
29	High Prevalence of Hepatitis C Virus (HCV) RNA in Dialysis Patients: Failure of Commercially Available Antibody Tests to Identify a Significant Number of Patients with HCV Infection. Journal of Infectious Diseases, 1993, 168, 1343-1348.	4.0	163
30	Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4370-4375.	7.1	155
31	A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans. PLoS ONE, 2013, 8, e59776.	2.5	151
32	Isolation and Characterization of Broadly Neutralizing Human Monoclonal Antibodies to the E1 Glycoprotein of Hepatitis C Virus. Journal of Virology, 2008, 82, 966-973.	3.4	150
33	Vaccination of Chimpanzees With Plasmid DNA Encoding the Hepatitis C Virus(HCV) Envelope E2 Protein Modified the Infection After Challenge With Homologous Monoclonal HCV. Hepatology, 2000, 32, 618-625.	7.3	149
34	Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. Journal of General Virology, 2016, 97, 2894-2907.	2.9	139
35	Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13318-13323.	7.1	136
36	Differential Efficacy of Protease Inhibitors Against HCV Genotypes 2a, 3a, 5a, and 6a NS3/4A Protease Recombinant Viruses. Gastroenterology, 2011, 141, 1067-1079.	1.3	134

#	Article	IF	Citations
37	Recombinant HCV Variants With NS5A From Genotypes 1â€“7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-Î±. Gastroenterology, 2011, 140, 1032-1042.e6.	1.3	132
38	Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends in Microbiology, 1999, 7, 402-410.	7.7	130
39	Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization. Journal of Virology, 2011, 85, 2224-2234.	3.4	128
40	Toward a Surrogate Model for Hepatitis C Virus: An Infectious Molecular Clone of the GB Virus-B Hepatitis Agent. Virology, 1999, 262, 470-478.	2.4	126
41	Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liverâ€“chimeric mice from infection with a homologous hepatitis C virus strain. Hepatology, 2008, 47, 1846-1855.	7.3	124
42	Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. Virus Research, 2018, 248, 53-62.	2.2	124
43	Novel Infectious cDNA Clones of Hepatitis C Virus Genotype 3a (Strain S52) and 4a (Strain ED43): Genetic Analyses and In Vivo Pathogenesis Studies. Journal of Virology, 2010, 84, 5277-5293.	3.4	122
44	Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step. Journal of Virology, 2011, 85, 7005-7019.	3.4	120
45	Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells. Antimicrobial Agents and Chemotherapy, 2012, 56, 5365-5373.	3.2	117
46	Animal Models for the Study of Hepatitis C Virus Infection and Related Liver Disease. Gastroenterology, 2012, 142, 1279-1287.e3.	1.3	117
47	In vivoevaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology, 2011, 53, 755-762.	7.3	115
48	Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19757-19762.	7.1	109
49	Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 Glycoprotein. Journal of Virology, 2013, 87, 37-51.	3.4	109
50	A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology, 2006, 44, 1355-1361.	7.3	105
51	Highly Efficient JFH1â€Based Cellâ€Culture System for Hepatitis C Virus Genotype 5a: Failure of Homologous Neutralizingâ€Antibody Treatment to Control Infection. Journal of Infectious Diseases, 2008, 198, 1756-1765.	4.0	101
52	Mouse models of acute and chronic hepacivirus infection. Science, 2017, 357, 204-208.	12.6	99
53	Hepatitis C Virus Cell-Cell Transmission and Resistance to Direct-Acting Antiviral Agents. PLoS Pathogens, 2014, 10, e1004128.	4.7	97
54	Vaccine-Induced Cross-Genotype Reactive Neutralizing Antibodies Against Hepatitis C Virus. Journal of Infectious Diseases, 2011, 204, 1186-1190.	4.0	91

#	Article	IF	Citations
55	Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1â€“7 and Escape Variants. Gastroenterology, 2018, 154, 1435-1448.	1.3	89
56	Five New or Recently Discovered (GBV-A) Virus Species Are Indigenous to New World Monkeys and May Constitute a Separate Genus of theFlaviviridae. Virology, 1997, 229, 429-436.	2.4	88
57	Chapter 2 Cutting the Gordian Knot-Development and Biological Relevance of Hepatitis C Virus Cell Culture Systems. Advances in Virus Research, 2008, 71, 51-133.	2.1	88
58	Previously Infected Chimpanzees Are Not Consistently Protected against Reinfection or Persistent Infection after Reexposure to the Identical Hepatitis C Virus Strain. Journal of Virology, 2008, 82, 8183-8195.	3.4	81
59	Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1101-10.	7.1	78
60	Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir. Gastroenterology, 2016, 151, 973-985.e2.	1.3	78
61	Development and Application of Hepatitis C Reporter Viruses with Genotype 1 to 7 Core-Nonstructural Protein 2 (NS2) Expressing Fluorescent Proteins or Luciferase in Modified JFH1 NS5A. Journal of Virology, 2011, 85, 8913-8928.	3.4	77
62	Genetic and structural insights into broad neutralization of hepatitis C virus by human V _H 1-69 antibodies. Science Advances, 2019, 5, eaav1882.	10.3	77
63	THE MOLECULAR BIOLOGY OF HEPATITIS C VIRUS. Clinics in Liver Disease, 1999, 3, 693-716.	2.1	74
64	Host range studies of GB virus-B hepatitis agent, the closest relative of hepatitis C virus, in New World monkeys and chimpanzees. Journal of Medical Virology, 2001, 65, 694-697.	5.0	73
65	Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. Hepatology, 2014, 60, 1551-1562.	7.3	72
66	The quasispecies of hepatitis C virus and the host immune response. Seminars in Immunopathology, 1997, 19, 5-26.	4.0	70
67	Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity. Hepatology, 2016, 64, 1881-1892.	7.3	69
68	Challenge Pools of Hepatitis C Virus Genotypes 1â€“6 Prototype Strains: Replication Fitness and Pathogenicity in Chimpanzees and Human Liverâ€“Chimeric Mouse Models. Journal of Infectious Diseases, 2010, 201, 1381-1389.	4.0	67
69	Efficient Culture Adaptation of Hepatitis C Virus Recombinants with Genotype-Specific Core-NS2 by Using Previously Identified Mutations. Journal of Virology, 2011, 85, 2891-2906.	3.4	67
70	The challenge of developing a vaccine against hepatitis C virus. Journal of Hepatology, 2002, 37, 684-695.	3.7	64
71	Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors. Hepatology, 2014, 59, 395-407.	7.3	63
72	Comparative analysis of the molecular mechanisms of recombination in hepatitis C virus. Trends in Microbiology, 2014, 22, 354-364.	7.7	63

#	Article	IF	Citations
73	Studies of Hepatitis C Virus in Chimpanzees and Their Importance for Vaccine Development. Intervirology, 2001, 44, 132-142.	2.8	59
74	Hepatitis C Virus Subtyping by a Core-Envelope 1-Based Reverse Transcriptase PCR Assay with Sequencing and Its Use in Determining Subtype Distribution among Danish Patients. Journal of Clinical Microbiology, 2003, 41, 1091-1100.	3.9	59
75	How Escherichia coli can bias the results of molecular cloning: Preferential selection of defective genomes of hepatitis C virus during the cloning procedure. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 13909-13914.	7.1	58
76	Differential Sensitivity of 5â€²UTR-NS5A Recombinants of Hepatitis CÂVirus Genotypes 1â˜6 to Protease and NS5A Inhibitors. Gastroenterology, 2014, 146, 812-821.e4.	1.3	58
77	Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication. Antimicrobial Agents and Chemotherapy, 2021, 65, e0009721.	3.2	58
78	Enhanced and Sustained CD8+ T Cell Responses with an Adenoviral Vector-Based Hepatitis C Virus Vaccine Encoding NS3 Linked to the MHC Class II Chaperone Protein Invariant Chain. Journal of Immunology, 2011, 186, 2355-2364.	0.8	57
79	Experimental Infection of Chimpanzees with Hepatitis C Virus of Genotype 5a: Genetic Analysis of the Virus and Generation of a Standardized Challenge Pool. Journal of Infectious Diseases, 1998, 178, 1193-1197.	4.0	56
80	In vitro efficacy of artemisinin-based treatments against SARS-CoV-2. Scientific Reports, 2021, 11, 14571.	3.3	53
81	Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. Virology, 2008, 376, 397-407.	2.4	52
82	In Vivo Study of the HC-TN Strain of Hepatitis C Virus Recovered from a Patient with Fulminant Hepatitis: RNA Transcripts of a Molecular Clone (pHC-TN) Are Infectious in Chimpanzees but Not in Huh7.5 Cells. Journal of Virology, 2007, 81, 7208-7219.	3.4	47
83	Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Hepatology, 2013, 58, 1587-1597.	7.3	47
84	Efficient Infectious Cell Culture Systems of the Hepatitis C Virus (HCV) Prototype Strains HCV-1 and H77. Journal of Virology, 2015, 89, 811-823.	3.4	47
85	Hepatitis C Virus Envelope Protein E2 Binds to CD81 of Tamarins. Virology, 2000, 277, 358-367.	2.4	46
86	Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Hepatology, 2019, 70, 771-787.	7.3	46
87	Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. Frontiers in Immunology, 2018, 9, 2146.	4.8	45
88	Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathogens, 2019, 15, e1007772.	4.7	45
89	Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10039-10047.	7.1	44
90	Amplification of the full-length hepatitis A virus genome by long reverse transcription-PCR and transcription of infectious RNA directly from the amplicon.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4370-4373.	7.1	43

#	Article	IF	Citations
91	Productive Homologous and Non-homologous Recombination of Hepatitis C Virus in Cell Culture. PLoS Pathogens, 2013, 9, e1003228.	4.7	43
92	Hypervariable Region 1 Deletion and Required Adaptive Envelope Mutations Confer Decreased Dependency on Scavenger Receptor Class B Type I and Low-Density Lipoprotein Receptor for Hepatitis C Virus. Journal of Virology, 2014, 88, 1725-1739.	3.4	43
93	HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Gastroenterology, 2018, 154, 2194-2208.e12.	1.3	41
94	Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge. Journal of Virology, 2015, 89, 9128-9132.	3.4	40
95	Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. Antiviral Research, 2018, 158, 264-287.	4.1	40
96	In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms. Frontiers in Microbiology, 2021, 12, 698944.	3.5	40
97	Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance. Antimicrobial Agents and Chemotherapy, 2015, 59, 7426-7436.	3.2	39
98	Characterization of Modified Hepatitis C Virus E2 Proteins Expressed on the Cell Surface. Virology, 2000, 274, 75-85.	2.4	38
99	HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice. Gut, 2016, 65, 1988-1997.	12.1	38
100	DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine, 2002, 20, 3263-3271.	3.8	37
101	In Vivo Analysis of the 3â€² Untranslated Region of GB Virus B after In Vitro Mutagenesis of an Infectious cDNA Clone: Persistent Infection in a Transfected Tamarin. Journal of Virology, 2004, 78, 9389-9399.	3.4	37
102	Interleukinâ€28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIVâ€1â€infected cohort. Journal of Viral Hepatitis, 2011, 18, e66-74.	2.0	36
103	Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1a, 2a, and 3a Viruses. Antimicrobial Agents and Chemotherapy, 2013, 57, 1291-1303.	3.2	35
104	Analysis of Functional Differences between Hepatitis C Virus NS5A of Genotypes 1â€“7 in Infectious Cell Culture Systems. PLoS Pathogens, 2012, 8, e1002696.	4.7	34
105	HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. Journal of Hepatology, 2019, 70, 388-397.	3.7	34
106	Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model. Scientific Reports, 2018, 8, 4619.	3.3	33
107	Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cellâ€“Based Vaccine Development. Gastroenterology, 2020, 158, 1058-1071.e6.	1.3	33
108	Functional analyses of GB virus B p13 protein: Development of a recombinant GB virus B hepatitis virus with a p7 protein. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3345-3350.	7.1	31

#	Article	IF	Citations
109	Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature. Virology, 2012, 422, 174-184.	2.4	29
110	Global and local envelope protein dynamics of hepatitis C virus determine broad antibody sensitivity. Science Advances, 2020, 6, eabb5938.	10.3	29
111	Transmission of Clonal Hepatitis C Virus Genomes Reveals the Dominant but Transitory Role of CD8 ⁺ T Cells in Early Viral Evolution. Journal of Virology, 2011, 85, 11833-11845.	3.4	28
112	Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro. Antimicrobial Agents and Chemotherapy, 2021, 65, e0268020.	3.2	28
113	Development of a TaqMan assay for the six major genotypes of hepatitis C virus: Comparison with commercial assays. Journal of Medical Virology, 2008, 80, 72-79.	5.0	27
114	Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. Journal of Virology, 2015, 89, 7758-7775.	3.4	26
115	An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. Science Advances, 2020, 6, eabb5642.	10.3	26
116	Identification of Alpha Interferon-Induced Envelope Mutations of Hepatitis C Virus In Vitro Associated with Increased Viral Fitness and Interferon Resistance. Journal of Virology, 2013, 87, 12776-12793.	3.4	25
117	Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle. Antimicrobial Agents and Chemotherapy, 2016, 60, 3563-3578.	3.2	25
118	A milestone for hepatitis C virus research: A virus generated in cell culture is fully viable in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3500-3501.	7.1	24
119	Hepatitis C homolog in dogs with respiratory illness. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12563-12564.	7.1	24
120	Characterization of Hepatitis C Virus Recombinants with Chimeric E1/E2 Envelope Proteins and Identification of Single Amino Acids in the E2 Stem Region Important for Entry. Journal of Virology, 2013, 87, 1385-1399.	3.4	23
121	Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. PLoS Pathogens, 2017, 13, e1006214.	4.7	23
122	Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. Scientific Reports, 2020, 10, 16261.	3.3	23
123	Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. Immunity, 2021, 54, 781-796.e4.	14.3	23
124	Hepatitis C virus expressing flag-tagged envelope protein 2 has unaltered infectivity and density, is specifically neutralized by flag antibodies and can be purified by affinity chromatography. Virology, 2011, 409, 148-155.	2.4	22
125	Non-genotype-specific role of the hepatitis C virus 5â€² untranslated region in virus production and in inhibition by interferon. Virology, 2011, 421, 222-234.	2.4	21
126	Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing coreâ€“NS2 and NS5A of genotypes 1â€“7. Journal of General Virology, 2013, 94, 2221-2235.	2.9	21

#	Article	IF	Citations
127	Transfusionâ€associated hepatitis before the screening of blood for hepatitis risk factors. Transfusion, 2014, 54, 2833-2841.	1.6	21
128	HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen. Scientific Reports, 2019, 9, 14085.	3.3	21
129	Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms. Journal of Virology, 2019, 93, .	3.4	21
130	Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins. Journal of General Virology, 2010, 91, 727-733.	2.9	20
131	Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study. BMC Infectious Diseases, 2011, 11, 177.	2.9	20
132	Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1â€“6. Virology, 2014, 458-459, 190-208.	2.4	20
133	Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir. Journal of General Virology, 2016, 97, 1381-1394.	2.9	18
134	Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro. Viruses, 2021, 13, 2082.	3.3	18
135	Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication. Viruses, 2022, 14, 172.	3.3	18
136	Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor. Antimicrobial Agents and Chemotherapy, 2013, 57, 6034-6049.	3.2	17
137	Broadening CD4⁺and CD8⁺T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes. Journal of Virology, 2017, 91, .	3.4	17
138	Equine pegiviruses cause persistent infection of bone marrow and are not associated with hepatitis. PLoS Pathogens, 2020, 16, e1008677.	4.7	17
139	Current status of a hepatitis C vaccine: Encouraging results but significant challenges ahead. Current Infectious Disease Reports, 2007, 9, 94-101.	3.0	16
140	Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. Scandinavian Journal of Gastroenterology, 2018, 53, 849-856.	1.5	16
141	Full-Length Open Reading Frame Amplification of Hepatitis C Virus. Methods in Molecular Biology, 2019, 1911, 85-91.	0.9	16
142	Hepatitis C Virusâ€“Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance. Journal of Infectious Diseases, 2019, 219, 68-79.	4.0	15
143	High-level expression of hepatitis C virus (HCV) structural proteins by a chimeric HCV/BVDV genome propagated as a BVDV pseudotype. Journal of Virological Methods, 2001, 97, 113-123.	2.1	14
144	Immunity against the GBVâ€B hepatitis virus in tamarins can prevent productive infection following rechallenge and is longâ€lived. Journal of Medical Virology, 2008, 80, 87-94.	5.0	14

#	Article	IF	Citations
145	Cell-culture-derived HCVâ€”a promising vaccine antigen. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 508-509.	17.8	14
146	Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines, 2020, 8, 294.	4.4	14
147	Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	14
148	SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor. Vaccines, 2021, 9, 706.	4.4	14
149	Pathogenesis, MicroRNAâ€122 Geneâ€Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection. Hepatology, 2021, 74, 1148-1163.	7.3	14
150	Acute GB virus B infection of marmosets is accompanied by mutations in the NS5A protein. Virus Research, 2005, 114, 154-157.	2.2	13
151	Monitoring of Hepatitis C Virus Quasispecies in Chronic Infection by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Mutation Detection. Journal of Clinical Microbiology, 2007, 45, 1053-1057.	3.9	13
152	Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells. Journal of Virology, 2019, 93, .	3.4	13
153	Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19. EBioMedicine, 2021, 71, 103519.	6.1	13
154	Molecular and epidemiological profiles of hepatitis C virus genotype 4 in Denmark. Journal of Medical Virology, 2010, 82, 1869-1877.	5.0	12
155	Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. Journal of Virology, 2018, 92, .	3.4	12
156	Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a. Journal of General Virology, 2018, 99, 1066-1077.	2.9	12
157	Diagnostic and clinical implications of the different genotypes of hepatitis C virus. Hepatology, 1994, 20, 256-259.	7.3	11
158	Nationwide Experience of Treatment with Protease Inhibitors in Chronic Hepatitis C Patients in Denmark: Identification of Viral Resistance Mutations. PLoS ONE, 2014, 9, e113034.	2.5	11
159	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. Nature Communications, 2021, 12, 6105.	12.8	11
160	Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. Journal of Hepatology, 2022, 76, 1051-1061.	3.7	11
161	Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	10
162	High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals. Scientific Reports, 2018, 8, 17505.	3.3	10

#	Article	IF	Citations
163	Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent. Virology, 2020, 540, 132-140.	2.4	10
164	Inferior cure rate in pilot study of 4â€week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C. Liver International, 2021, 41, 2601-2610.	3.9	9
165	Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome. PLoS ONE, 2013, 8, e62674.	2.5	8
166	Virus Adaptation and Selection Following Challenge of Animals Vaccinated against Classical Swine Fever Virus. Viruses, 2019, 11, 932.	3.3	8
167	Evolutionary selection of pestivirus variants with altered or no microRNA dependency. Nucleic Acids Research, 2020, 48, 5555-5571.	14.5	8
168	Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1. Current Opinion in Virology, 2021, 50, 69-75.	5.4	8
169	Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNAâ€“mRNA or Vectorâ€“mRNA COVID-19 Vaccines. Vaccines, 2022, 10, 75.	4.4	8
170	Neutralization and receptor use of infectious cultureâ€“derived rat hepacivirus as a model for HCV. Hepatology, 2022, 76, 1506-1519.	7.3	8
171	Correlates of spontaneous clearance of hepatitis C virus in a Danish human immunodeficiency virus type 1 cohort. Scandinavian Journal of Infectious Diseases, 2011, 43, 798-803.	1.5	7
172	Neutralizing Antibodies to Hepatitis C Virus in Perinatally Infected Children Followed Up Prospectively. Journal of Infectious Diseases, 2011, 204, 1741-1745.	4.0	7
173	Persistent human hepatitis B virus infection in cynomolgus monkeys: A novel animal model in the search for a cure?. Hepatology, 2013, 58, 1533-1536.	7.3	7
174	Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study. European Journal of Gastroenterology and Hepatology, 2018, 30, 1177-1186.	1.6	7
175	Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
176	Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel nonâ€target sites, for DAAâ€based treatment and retreatment outcome. Journal of Viral Hepatitis, 2021, 28, 302-316.	2.0	7
177	Lipid Droplets Accumulation during Hepatitis C Virus Infection in Cell-Culture Varies among Genotype 1â€“3 Strains and Does Not Correlate with Virus Replication. Viruses, 2021, 13, 389.	3.3	7
178	HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4. Gut, 2022, 71, 627-642.	12.1	7
179	In Vitro Neutralization Assay Using Cultured Hepatitis C Virus. Methods in Molecular Biology, 2019, 1911, 433-439.	0.9	7
180	Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon. Journal of General Virology, 2020, 101, 1182-1190.	2.9	6

#	Article	IF	Citations
181	Hepatitis C virusâ€“host cell interactions uncovered. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13215-13216.	7.1	4
182	Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology, 2018, 522, 177-192.	2.4	4
183	Importance of the polymerase chain reaction in the study of hepatitis C virus infection. International Journal of Clinical and Laboratory Research, 1993, 23, 139-145.	1.0	3
184	Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 2012, 47, 1115-1119.	1.5	3
185	Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle. Microbiology Resource Announcements, 2019, 8, .	0.6	3
186	Reflections on the History of HCV: A Posthumous Examination. Clinical Liver Disease, 2020, 15, S64-S71.	2.1	3
187	In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus. PLoS Pathogens, 2021, 17, e1009720.	4.7	3
188	Long PCR Amplification of Large Fragments of Viral Genomes. , 2003, , 167-172.		3
189	A Distinct Dexamethasone-Dependent Gene Expression Profile in the Lungs of COVID-19 Patients. Journal of Infectious Diseases, 2022, 226, 2137-2141.	4.0	3
190	Long PCR Methodology. , 2003, 226, 173-178.		2
191	Analysis of Virus Population Profiles within Pigs Infected with Virulent Classical Swine Fever Viruses: Evidence for Bottlenecks in Transmission but Absence of Tissue-Specific Virus Variants. Journal of Virology, 2020, 94, .	3.4	2
192	Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. PLoS ONE, 2021, 16, e0255336.	2.5	2
193	Identification of specific amino acid residues in the border disease virus glycoprotein E2 that modify virus growth in pig cells but not in sheep cells. Journal of General Virology, 2020, 101, 1170-1181.	2.9	2
194	Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment. Microbiology Resource Announcements, 2021, 10, e0075521.	0.6	2
195	High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor. Vaccines, 2022, 10, 249.	4.4	2
196	Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment. Journal of Clinical Virology, 2022, 150-151, 105159.	3.1	2
197	Vaccines against hepatitis C: a travel into neutralisation space. Gut, 2021, 70, 1609-1610.	12.1	1
198	Neutralizing Antibodies Against Hepatitis C Virus and Their Role in Vaccine Immunity. Gastroenterology, 2022, 162, 396-398.	1.3	1

#	Article	IF	Citations
199	High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system. Virus Evolution, 2022, 8, veab106.	4.9	1
200	Natural History and Experimental Models. , 0, , 439-467.		1
201	Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection. Journal of Medical Virology, 2016, 88, 1791-1803.	5.0	0
202	Identification of Novel Determinants of Neutralization Epitope Shielding for Hepatitis C Virus in Vitro. Proceedings (mdpi), 2020, 50, .	0.2	0
203	Hepatitis C Virus Replication in Cell Culture. , 2004, , 108-122.		0